We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Cellectricon Presents Transfection Solutions for Drug Discovery at Experimental Biology 2013

Listen with
Speechify
0:00
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute

Cellectricon will be exhibiting its revolutionary in-situ transfection technology platforms on booth #1178 at the Experimental Biology conference (20-24 April, Boston, US).

Cellectricon will also present two posters on April 24, focusing on high performance in-situ transfection.

The poster “Transfection of primary and iPSC-derived cells by capillary electroporation” (LB162) explores how Cellectricon’s novel electroporation Cellaxess® ACE system is ideal for in-situ transfection of any adherent cell type.

Minimal cell processing and low voltages ensure excellent viability and completely retained morphology, in any cell culture format.

For in-situ transfection applications on a larger scale, the poster “High throughput in-situ transfection of primary and iPSC-derived cells” (LB163) details how the novel electroporation platform Cellaxess® Elektra is optimized for in-vitro transfection of primary and iPSC-derived cells, directly into 384-well plates.

With virtually no impact on cell viability or morphology, this system is ideal for screening applications such as cDNA and RNAi.

The presentations will commence from 12:15 to 13:30, and posters will be available for viewing throughout the day.